106
Participants
Start Date
March 17, 2022
Primary Completion Date
February 6, 2025
Study Completion Date
February 6, 2025
SL-172154
The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Azacitidine (AZA)
Chemotherapy drug approved for use in MDS and AML.
Venetoclax
Drug approved for use in AML.
Roswell Park Comprehensive Cancer Center, Buffalo
UPMC Hillman Cancer Center, Pittsburgh
VCU Massey Cancer Center, Richmond
University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill
Moffitt Cancer Center, Tampa
Norton Cancer Institute, Louisville
University of Cincinnati Medical Center, Cincinnati
University of Michigan, Ann Arbor
START Midwest, Grand Rapids
The University of Chicago, Chicago
Baylor Scott & White Research Institute, Dallas
MD Anderson Cancer Center, Houston
UCLA Medical Center-Bowyer Oncology Center, Los Angeles
City of Hope, Duarte
Yale Cancer Center, New Haven
Dana-Farber Cancer Institute, Boston
Tom Baker Cancer Centre, Calgary
Princess Margaret Cancer Centre, Toronto
Jewish General Hospital, Montreal
King's College Hospital NHS Foundation Trust, London
University Hospitals Plymouth NHS Trust, Derriford Hospital, Crownhill
Imperial College Healthcare NHS Trust, London
The Christie NHS Foundation Trust, Manchester
Shattuck Labs, Inc.
INDUSTRY